#154149

MDA-MB-231 TetOn-3G MRCKBeta cell line

Please Enter Your Email ID
Email ID

Cat. #154149

MDA-MB-231 TetOn-3G MRCKBeta cell line

Cat. #: 154149

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Transgenic

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Daniel Croft ; Justin Bower ; Heather Mckinnon

Institute: Cancer Research UK, Glasgow: The Beatson Institute

Tool Details
Target Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MDA-MB-231 TetOn-3G MRCKBeta cell line
  • Alternate name: Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta
  • Cancer: Breast cancer
  • Cancers detailed: Triple negative breast (TNBC)
  • Research fields: Cancer;Cell biology;Drug development;Genetics
  • Tool sub type: Continuous
  • Parental cell: MDA-MB-231 D3H2LN-Luc cell line
  • Organism: Human
  • Tissue: Breast
  • Disease: Cancer
  • Growth properties: Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline.
  • Model: Transgenic
  • Conditional: Yes
  • Conditional description: MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of MRCKÎ?‹Â›. Therefore MRCKÎ?‹Â› expression is induced in the presence of doxycycline.
  • Description: This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK?. MRCK? is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK?, in conjunction with MRCKa, ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Useful for the study of breast cancer cell cytoskeleton reorganisation and cell migration. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors. Treatment with doxycycline induced MRCKÎ?‹Â› kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested.
  • Biosafety level: 1
  • Additional notes: Treatment with doxycycline induced MRCK? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested. Tet-On System owned by TET Systems GmbH & Co. KG.
  • Recommended controls: MDA-MB-231 D3H2LN-Luc parental line

Target Details

  • Target: MRCKÎ?‹Â›

Handling

  • Format: Frozen
  • Growth medium: 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205.
  • A novel small-molecule MRCK inhibitor blocks cancer cell invasion.